Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.71
NVRO's Cash-to-Debt is ranked lower than
53% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. NVRO: 1.71 )
Ranked among companies with meaningful Cash-to-Debt only.
NVRO' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.71  Med: 5.15 Max: No Debt
Current: 1.71
1.71
No Debt
Equity-to-Asset 0.54
NVRO's Equity-to-Asset is ranked lower than
64% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NVRO: 0.54 )
Ranked among companies with meaningful Equity-to-Asset only.
NVRO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.54  Med: 0.6 Max: 0.89
Current: 0.54
0.54
0.89
Debt-to-Equity 0.62
NVRO's Debt-to-Equity is ranked lower than
72% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 0.30 vs. NVRO: 0.62 )
Ranked among companies with meaningful Debt-to-Equity only.
NVRO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08  Med: 0.55 Max: 0.62
Current: 0.62
0.08
0.62
Debt-to-EBITDA -5.30
NVRO's Debt-to-EBITDA is ranked lower than
99.99% of the 158 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. NVRO: -5.30 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NVRO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.35  Med: -3.46 Max: -0.31
Current: -5.3
-6.35
-0.31
Piotroski F-Score: 5
Altman Z-Score: 4.28
Beneish M-Score: -2.41
WACC vs ROIC
5.84%
-28.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -9.36
NVRO's Operating Margin % is ranked lower than
62% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. NVRO: -9.36 )
Ranked among companies with meaningful Operating Margin % only.
NVRO' s Operating Margin % Range Over the Past 10 Years
Min: -107.03  Med: -88.25 Max: -9.05
Current: -9.36
-107.03
-9.05
Net Margin % -11.64
NVRO's Net Margin % is ranked lower than
63% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. NVRO: -11.64 )
Ranked among companies with meaningful Net Margin % only.
NVRO' s Net Margin % Range Over the Past 10 Years
Min: -110.7  Med: -95.54 Max: -11.22
Current: -11.64
-110.7
-11.22
ROE % -17.91
NVRO's ROE % is ranked lower than
64% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. NVRO: -17.91 )
Ranked among companies with meaningful ROE % only.
NVRO' s ROE % Range Over the Past 10 Years
Min: -47.12  Med: -29.45 Max: -13.14
Current: -17.91
-47.12
-13.14
ROA % -9.81
NVRO's ROA % is ranked lower than
60% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: -0.26 vs. NVRO: -9.81 )
Ranked among companies with meaningful ROA % only.
NVRO' s ROA % Range Over the Past 10 Years
Min: -41.78  Med: -24.7 Max: -8.29
Current: -9.81
-41.78
-8.29
ROC (Joel Greenblatt) % -25.54
NVRO's ROC (Joel Greenblatt) % is ranked lower than
61% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 3.87 vs. NVRO: -25.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NVRO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -244.06  Med: -160.81 Max: -21.89
Current: -25.54
-244.06
-21.89
3-Year Revenue Growth Rate 14.80
NVRO's 3-Year Revenue Growth Rate is ranked higher than
76% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. NVRO: 14.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NVRO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -53.9  Med: -33.1 Max: 14.8
Current: 14.8
-53.9
14.8
3-Year EBITDA Growth Rate 51.40
NVRO's 3-Year EBITDA Growth Rate is ranked higher than
91% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 7.50 vs. NVRO: 51.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NVRO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 51.4  Med: 56.2 Max: 70.2
Current: 51.4
51.4
70.2
3-Year EPS without NRI Growth Rate 43.50
NVRO's 3-Year EPS without NRI Growth Rate is ranked higher than
87% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 7.80 vs. NVRO: 43.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NVRO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 43.5 Max: 66.5
Current: 43.5
0
66.5
GuruFocus has detected 1 Warning Sign with Nevro Corp NVRO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NVRO's 30-Y Financials

Financials (Next Earnings Date: 2019-02-23 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

NVRO Guru Trades in Q4 2017

Paul Tudor Jones 2,958 sh (New)
Mario Gabelli 6,000 sh (New)
Chuck Royce 36,000 sh (+50.00%)
Steven Cohen 819,661 sh (+50.96%)
Pioneer Investments 160,040 sh (+285.14%)
Ron Baron 21,300 sh (unchged)
» More
Q1 2018

NVRO Guru Trades in Q1 2018

Joel Greenblatt 9,622 sh (New)
Ron Baron 30,300 sh (+42.25%)
Paul Tudor Jones 5,961 sh (+101.52%)
Pioneer Investments 212,640 sh (+32.87%)
Chuck Royce 36,000 sh (unchged)
Mario Gabelli 6,000 sh (unchged)
Steven Cohen 442,782 sh (-45.98%)
» More
Q2 2018

NVRO Guru Trades in Q2 2018

Paul Tudor Jones 6,362 sh (+6.73%)
Pioneer Investments 251,440 sh (+18.25%)
Ron Baron Sold Out
Joel Greenblatt Sold Out
Chuck Royce 23,000 sh (-36.11%)
Steven Cohen 84,962 sh (-80.81%)
Mario Gabelli 5,000 sh (-16.67%)
» More
Q3 2018

NVRO Guru Trades in Q3 2018

Mario Gabelli 16,200 sh (+224.00%)
Steven Cohen 1,490,642 sh (+1654.48%)
Paul Tudor Jones 15,926 sh (+150.33%)
Chuck Royce Sold Out
Pioneer Investments 74,787 sh (-70.26%)
» More
» Details

Insider Trades

Latest Guru Trades with NVRO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Nevro Corp does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NAS:INGN, NAS:NUVA, XSWX:TECN, TSE:8086, TSE:6849, SZSE:300529, HKSE:01066, TSE:7575, NAS:WMGI, XSWX:YPSN, OCSE:OSSR, NYSE:ITGR, NAS:CNMD, TSE:3360, SZSE:300633, SZSE:002223, XTAE:MZOR, SZSE:300298, XTER:DRW3, SHSE:603579 » details
Traded in other countries:1N7.Germany,
Headquarter Location:USA
Nevro Corp develops and sells medical devices mainly in the United States. Its main product is the Senza system which is intended to relieve leg and spinal cord pain with the application of the HF10 therapy.

Nevro Corp is a medical device company. Its key product is the Senza spinal cord stimulation system, a neuromodulation platform for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. Nevro generates the majority of its revenue in the United States. It also receives nearly half of its revenue from Australia, the United Kingdom, and Germany.

Top Ranked Articles about Nevro Corp

Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Nevro Corporation (NVRO) and Encourages NVRO Investors to Contact the Firm
Nevro Reports Third Quarter 2018 Financial Results
SHAREHOLDER ALERT: AMPE NVRO PZZA OPK QRTEA MCHP COCP TGTX CPB TRVN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nevro Corporation To Contact The Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nevro Corporation - NVRO
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AMPE, NVRO, LCI, LOGM and HTHT
FINAL DEADLINE ALERT:  Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Nevro Corp. (NYSE: NVRO) To Contact The Firm
SHAREHOLDER ALERT: NVRO LCI CBS PZZA LOGM SKX OPK PM: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEVRO SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Nevro Corp. - NVRO
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nevro Corporation - NVRO

Ratios

vs
industry
vs
history
PB Ratio 4.87
NVRO's PB Ratio is ranked lower than
87% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. NVRO: 4.87 )
Ranked among companies with meaningful PB Ratio only.
NVRO' s PB Ratio Range Over the Past 10 Years
Min: 4.36  Med: 8.4 Max: 12.06
Current: 4.87
4.36
12.06
PS Ratio 3.13
NVRO's PS Ratio is ranked lower than
74% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. NVRO: 3.13 )
Ranked among companies with meaningful PS Ratio only.
NVRO' s PS Ratio Range Over the Past 10 Years
Min: 1.5  Med: 8.96 Max: 35.2
Current: 3.13
1.5
35.2
EV-to-EBIT -33.95
NVRO's EV-to-EBIT is ranked lower than
99.99% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 24.76 vs. NVRO: -33.95 )
Ranked among companies with meaningful EV-to-EBIT only.
NVRO' s EV-to-EBIT Range Over the Past 10 Years
Min: -114.2  Med: -57.4 Max: -14.6
Current: -33.95
-114.2
-14.6
EV-to-EBITDA -38.20
NVRO's EV-to-EBITDA is ranked lower than
99.99% of the 188 Companies
in the Global Medical Devices industry.

( Industry Median: 18.14 vs. NVRO: -38.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVRO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -123.1  Med: -64.9 Max: -14.7
Current: -38.2
-123.1
-14.7
EV-to-Revenue 2.88
NVRO's EV-to-Revenue is ranked lower than
72% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 3.73 vs. NVRO: 2.88 )
Ranked among companies with meaningful EV-to-Revenue only.
NVRO' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.9  Med: 11.5 Max: 33.6
Current: 2.88
2.9
33.6
Current Ratio 8.05
NVRO's Current Ratio is ranked higher than
90% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. NVRO: 8.05 )
Ranked among companies with meaningful Current Ratio only.
NVRO' s Current Ratio Range Over the Past 10 Years
Min: 6.15  Med: 9.71 Max: 18.63
Current: 8.05
6.15
18.63
Quick Ratio 6.31
NVRO's Quick Ratio is ranked higher than
88% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. NVRO: 6.31 )
Ranked among companies with meaningful Quick Ratio only.
NVRO' s Quick Ratio Range Over the Past 10 Years
Min: 4.76  Med: 7.88 Max: 17.25
Current: 6.31
4.76
17.25
Days Inventory 316.60
NVRO's Days Inventory is ranked lower than
85% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 143.61 vs. NVRO: 316.60 )
Ranked among companies with meaningful Days Inventory only.
NVRO' s Days Inventory Range Over the Past 10 Years
Min: 316.6  Med: 391.99 Max: 501.59
Current: 316.6
316.6
501.59
Days Sales Outstanding 71.58
NVRO's Days Sales Outstanding is ranked lower than
57% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 69.21 vs. NVRO: 71.58 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVRO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.58  Med: 93.48 Max: 118.1
Current: 71.58
71.58
118.1
Days Payable 66.56
NVRO's Days Payable is ranked higher than
56% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 58.34 vs. NVRO: 66.56 )
Ranked among companies with meaningful Days Payable only.
NVRO' s Days Payable Range Over the Past 10 Years
Min: 66.56  Med: 108.49 Max: 284.1
Current: 66.56
66.56
284.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.10
NVRO's 3-Year Average Share Buyback Ratio is ranked lower than
52% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: -5.70 vs. NVRO: -6.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVRO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -245.9  Med: -220.6 Max: -6.1
Current: -6.1
-245.9
-6.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 23.26
NVRO's Price-to-Net-Cash is ranked lower than
80% of the 104 Companies
in the Global Medical Devices industry.

( Industry Median: 14.24 vs. NVRO: 23.26 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NVRO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6.57  Med: 23.97 Max: 45.14
Current: 23.26
6.57
45.14
Price-to-Net-Current-Asset-Value 5.27
NVRO's Price-to-Net-Current-Asset-Value is ranked lower than
62% of the 207 Companies
in the Global Medical Devices industry.

( Industry Median: 7.79 vs. NVRO: 5.27 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NVRO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5.27  Med: 8.74 Max: 12.61
Current: 5.27
5.27
12.61
Price-to-Tangible-Book 4.88
NVRO's Price-to-Tangible-Book is ranked lower than
76% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 4.50 vs. NVRO: 4.88 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NVRO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.88  Med: 8.34 Max: 12.06
Current: 4.88
4.88
12.06
Price-to-Median-PS-Value 0.35
NVRO's Price-to-Median-PS-Value is ranked higher than
75% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. NVRO: 0.35 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NVRO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 0.99 Max: 3.76
Current: 0.35
0.2
3.76
Earnings Yield (Greenblatt) % -2.96
NVRO's Earnings Yield (Greenblatt) % is ranked lower than
57% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.74 vs. NVRO: -2.96 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NVRO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -6.8  Med: -1.7 Max: -0.9
Current: -2.96
-6.8
-0.9

More Statistics

Revenue (TTM) (Mil) $377.31
EPS (TTM) $ -1.46
Beta0.47
Volatility49.98%
52-Week Range $35.41 - 94.34
Shares Outstanding (Mil)30.16

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 385 420 462
EBIT (Mil $) -39 -12 -2
EBITDA (Mil $) -35 -8 3
EPS ($) -1.65 -0.95 -0.56
EPS without NRI ($) -1.65 -0.95 -0.56
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}